Last reviewed · How we verify
0.9% sterile Sodium Chloride solution for injection
At a glance
| Generic name | 0.9% sterile Sodium Chloride solution for injection |
|---|---|
| Also known as | Saline |
| Sponsor | Imperial College London |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Any Event in SOC
- Genitourinary chlamydia infection
- Upper respiratory tract infection
- COVID-19
- Headache
- Genitourinary tract gonococcal infection
- Nasopharyngitis
- Diabetes mellitus
- Influenza like illness
- Injection site pain
- Vulvovaginitis trichomonal
- Hypertension
Key clinical trials
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Comparison of the Effectiveness of Exercise, Dry Needling and Interfascial Block Treatments in the Treatment of Myofascial Pain Syndrome (NA)
- SCARFREE-001: Verteporfin for Scar Prevention (PHASE2)
- XVIE to Treat Androgenetic Alopecia (AGA) (PHASE1, PHASE2)
- Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction (PHASE2, PHASE3)
- Postop Pain Management in Pituitary Tumour Patients (PHASE4)
- Clinical Trial to Evaluate the Efficacy and Safety of SUBMO® as a Submucosal Injection Agent in Endoscopic Resection of Superficial Gastrointestinal Lesions. (NA)
- Phenol and Botulinum Toxin vs Botulinum Toxin Alone for Post-Stroke Upper-Limb Spasticity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: